{"log_id": 1001160589226950184, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 0.000175, "average": 0.994093, "min": 0.943091}, "location": {"width": 779, "top": 213, "height": 28, "left": 221}, "words": "及看护者应当每日对患者进行以上监察。使用本品时,处方应当从最小量开始,并配合良好"}, {"probability": {"variance": 0.000126, "average": 0.995871, "min": 0.952734}, "location": {"width": 318, "top": 260, "height": 25, "left": 221}, "words": "的患者管理,以减少过量用药的危险"}, {"probability": {"variance": 1.9e-05, "average": 0.997256, "min": 0.98714}, "location": {"width": 238, "top": 305, "height": 24, "left": 220}, "words": "2双相情感障碍患者的筛查"}, {"probability": {"variance": 0.002332, "average": 0.986359, "min": 0.713426}, "location": {"width": 740, "top": 349, "height": 26, "left": 261}, "words": "抑郁发作可能是双相情感障碍的初期表现。一般认为(虽然未通过对照试验明确),单"}, {"probability": {"variance": 2e-05, "average": 0.998497, "min": 0.972546}, "location": {"width": 782, "top": 394, "height": 26, "left": 222}, "words": "用抗抑郁药物治疗这类发作可能增加具有双相情感障碍危险患者的混合型/躁狂发作的可"}, {"probability": {"variance": 0.019953, "average": 0.915962, "min": 0.671346}, "location": {"width": 29, "top": 318, "height": 132, "left": 1142}, "words": "一食节附"}, {"probability": {"variance": 0.001695, "average": 0.991485, "min": 0.735604}, "location": {"width": 778, "top": 439, "height": 27, "left": 223}, "words": "能性。尚不明确以上提及的症状是否意味着可能出现这种转变。然而,在用抗抑郁药物开始"}, {"probability": {"variance": 1e-06, "average": 0.999322, "min": 0.995445}, "location": {"width": 777, "top": 485, "height": 25, "left": 223}, "words": "治疗之前,应当对有抑郁症状的患者进行充分的筛查,以确定他们是否具有双相情感障碍的"}, {"probability": {"variance": 0.008994, "average": 0.97772, "min": 0.454908}, "location": {"width": 780, "top": 529, "height": 26, "left": 222}, "words": "危险;该筛查应当包括自杀家族史,双相情感障碍和抑郁症家族史在内详细的精神病史。应"}, {"probability": {"variance": 0.000222, "average": 0.990996, "min": 0.942388}, "location": {"width": 473, "top": 575, "height": 25, "left": 224}, "words": "当注意本品未经批准用于治疗双相情感障碍的抑郁发作"}, {"probability": {"variance": 3e-06, "average": 0.998646, "min": 0.992887}, "location": {"width": 715, "top": 620, "height": 25, "left": 269}, "words": "对使用文拉法辛的所有患者应当给予适当监测和密切观察临床症状恶化和自杀行为"}, {"probability": {"variance": 1.3e-05, "average": 0.997688, "min": 0.983731}, "location": {"width": 777, "top": 663, "height": 26, "left": 223}, "words": "应当提醒患者、家人以及看护者警惕患者是否出现焦虑、激越、惊恐发作、失眠、易怒、敌"}, {"probability": {"variance": 0.0004, "average": 0.994751, "min": 0.872055}, "location": {"width": 777, "top": 708, "height": 26, "left": 224}, "words": "意、攻击性、冲动、静坐不能(精神运动性不安)、轻躁狂、躁狂、其它行为异常变化、抑"}, {"probability": {"variance": 0.000136, "average": 0.995402, "min": 0.943512}, "location": {"width": 776, "top": 752, "height": 25, "left": 225}, "words": "郁症状恶化以及出现自杀倾向的情况,尤其在开始治疗或者是改变剂量或改变剂量方案期间"}, {"probability": {"variance": 0.000373, "average": 0.992686, "min": 0.892973}, "location": {"width": 778, "top": 797, "height": 27, "left": 223}, "words": "必须考虑可能存在自杀企图的风险,尤其对抑郁症患者,应当给予最小包装量(即盒数)的"}, {"probability": {"variance": 0.001357, "average": 0.984092, "min": 0.855222}, "location": {"width": 453, "top": 843, "height": 24, "left": 223}, "words": "药物,同时对患者进行有效管理,以减少过量的风险"}, {"probability": {"variance": 0.000532, "average": 0.993393, "min": 0.892544}, "location": {"width": 730, "top": 887, "height": 26, "left": 270}, "words": "已知自杀行为预示着抑郁症和其他某些精神疾病的风险,反之这些疾病本身也是自杀"}, {"probability": {"variance": 3e-05, "average": 0.997646, "min": 0.972463}, "location": {"width": 777, "top": 932, "height": 25, "left": 223}, "words": "的高危因素。汇总分析短期、安慰剂对照试验显示治疗抑郁症和其他精神疾病时,抗抑郁药"}, {"probability": {"variance": 0.001949, "average": 0.983144, "min": 0.752353}, "location": {"width": 773, "top": 975, "height": 26, "left": 224}, "words": "物( SSRIS和其它)会增加儿童、青少年和青年(18~24岁)的自杀风险。短期的对照试验"}, {"probability": {"variance": 6.4e-05, "average": 0.996857, "min": 0.948373}, "location": {"width": 776, "top": 1020, "height": 26, "left": 223}, "words": "研究未显示在24岁以上的成人中使用抗抑郁药物,自杀的风险与安慰剂相比有所增加。在65"}, {"probability": {"variance": 0.013073, "average": 0.948917, "min": 0.411276}, "location": {"width": 750, "top": 1051, "height": 54, "left": 221}, "words": "岁及以上的成人中使用抗抑郁药物,自杀的风险与安慰剂比有所减少药业有"}, {"probability": {"variance": 0.007263, "average": 0.965403, "min": 0.711136}, "location": {"width": 159, "top": 1109, "height": 24, "left": 223}, "words": "3.5-羟色胺综合征"}, {"probability": {"variance": 0.010854, "average": 0.960108, "min": 0.461204}, "location": {"width": 715, "top": 1152, "height": 27, "left": 270}, "words": "已有包括本品在内的单用 SNRIS和 SSRIS发生可能威胁生命的5色胺综的报告"}, {"probability": {"variance": 0.000339, "average": 0.992092, "min": 0.910383}, "location": {"width": 776, "top": 1193, "height": 30, "left": 223}, "words": "特别是与其他拟5-羟色胺药(包括曲坦类药、三环抗抑郁药、芬太尼锂盐、曲马多、色氨"}, {"probability": {"variance": 0.008273, "average": 0.96781, "min": 0.505027}, "location": {"width": 778, "top": 1240, "height": 28, "left": 222}, "words": "酸、丁螺环酮和圣约翰草)合用时。也有用减少5-羟色胺代谢的药物发生5羟色胺综合的"}, {"probability": {"variance": 0.004846, "average": 0.979971, "min": 0.60445}, "location": {"width": 747, "top": 1286, "height": 26, "left": 222}, "words": "报告(特别是 MAOIS,,包括治疗精神病和其他疾病,例如利奈唑胺或静脉注射亚甲蓝)"}, {"probability": {"variance": 0.004625, "average": 0.976107, "min": 0.636166}, "location": {"width": 732, "top": 1330, "height": 26, "left": 266}, "words": "5-羟色胺综合征的症状可包括精神状态的变化(例如,激越、幻觉、谵妄和昏迷)、自"}, {"probability": {"variance": 0.003121, "average": 0.985391, "min": 0.647541}, "location": {"width": 777, "top": 1375, "height": 26, "left": 223}, "words": "主神经不稳定(例如,心动过速、血压不稳定、头晕、多汗、面红、高热)、神经肌肉症状"}, {"probability": {"variance": 0.009338, "average": 0.967699, "min": 0.509053}, "location": {"width": 748, "top": 1419, "height": 27, "left": 243}, "words": "例如,震颤、强直、肌阵挛、反射亢进、共济失调入、癫痫发作和或胃肠道症状(例如"}, {"probability": {"variance": 0.013936, "average": 0.962917, "min": 0.456882}, "location": {"width": 499, "top": 1465, "height": 25, "left": 225}, "words": "恶心、呕吐、腹泻)。应注意监测患者出现5-羟色胺综合征"}, {"probability": {"variance": 0.001924, "average": 0.984773, "min": 0.772815}, "location": {"width": 730, "top": 1509, "height": 25, "left": 268}, "words": "禁止本品与 MAOIS同时用于治疗精神病。正在用 MAOIS(例如,利奈唑胺或静脉注射"}], "language": 3}